

and The Stock Exchange of Hong Kong
of this announcement, make no
and expressly disclaim any liability
or in reliance upon the whole or any



Hepalink

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

ANNOUNCEMENT

PROPOSED AMENDMENTS TO THE ARTICLES

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the **Company**), a company registered in the People's Republic of China (the **PRC**) with a registered capital of RMB13.51 billion, listed on the Stock Exchange of Hong Kong Limited (the **Stock Exchange**) (the **Listing Rules**).

The Company is currently in the process of preparing the 2023 Financial Statements, and the Board of Directors (the **Board**) has held a meeting on December 15, 2023, to discuss and propose amendments to the Company's Articles of Association (the **Articles**). The Board has also held a meeting on December 15, 2023, to discuss and propose amendments to the Company's Articles of Association (the **Articles**). The Board has also held a meeting on December 15, 2023, to discuss and propose amendments to the Company's Articles of Association (the **Articles**).

The Board (the **Board**) has also held a meeting on December 15, 2023, to discuss and propose amendments to the Company's Articles of Association (the **Articles**).

On February 14, 2023, the State Council (the **State Council**) issued the Order of the State Council (the **PRC**) on the Decision of the State Council on the Abolition of Some Administrative Regulations and Documents (the **Decision**), which is effective from February 14, 2023. On February 17, 2023, the State Council issued the Order of the State Council on the Special Measures for the Overseas Issuance of Shares and Listing of Joint Stock Companies (the **Special Measures**), which is effective from February 17, 2023. On February 17, 2023, the State Council issued the Order of the State Council on the Trial Measures for the Overseas Issuance of Shares and Listing of Joint Stock Companies (the **Trial Measures**), which is effective from February 17, 2023.

1. 關於境外上市公司章程必備條款的通知》, T.D.C. and T.M., (c. , **New PRC Regulations**) a b c c Ma c 31, 2023.